M. Brian Fennerty, MD

M. Brian Fennerty, MD
Professor of Medicine
Division of Gastroenterology, OHSU
OHSU/ VAMC

• Degrees:
  B.S., Biology, State University of New York at Albany, NY
  M.D. – Creighton University, Omaha, Nebraska, 1980.

• Residency:
  Internal Medicine – Naval Hospital, San Diego, California, 1980-1984

• Fellowship:
  Gastroenterology – University of Arizona Health Sciences Center, Tucson, Arizona, 1987-1989.

• Research/Clinical Interests:
  Gastroesophageal Reflux, Barrett's Esophagus, Helicobacter pylori, Pharmacoeconomics, Outcomes Research, Ttherapeutic eendoscopy, Gastrointestinal Motility, Pancreaticobiliary Endoscopy.

• Representative Publications:
  
  • Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MB, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-18
    
  • Fass R, Fennerty MB, Roya T, Johnson C, Camargo l, Sampliner RE. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998;115:42-49.
    
  • Fennerty MB, Krause R, Huber M, Weissfeld A, Rose P, Siepman N. A comparison of 10 and14 days of lansoprazole triple therapy for eradication of H.pylori. Arch Int Med 1998;158:1651-1656.
    
  • Fennerty MB, Lieberman DA, Vakil N, Magaret N, Faigel DO, Helfand M. Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Int Med 1999; 159:1562-6.
    
  • Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton- pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998;129:547-550.
    
  • Margaret N, Burm M, Faigel D, Kelly C, Peterson W, Fennerty MB. A randomized trial of lansoprazole, amoxacillin and clrithromycin vs lansoprazole, bismuth, metronidazle and tetracycline in the retreatement of patients failing initial Helicobacter pylori therapy. Dig Dis 2001;19:174-8.
    
  • Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease-Current concepts and dilemmas. AM J Gatroenterol 2001;96:303-314.
    
  • Laine LA, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with non-ulcer dyspepsia: A meta-analysis of randomized, controlled trials. Ann Int Med 2001;134:361-369.
    
  • Laine LA, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with non-ulcer dyspepsia: a meta-analysis of randomized, controlled trials. Ann Int Med 2001;134:361-369.
    
  • Laine L, Fennerty MB, Osato M, Sugg J, Suchower L, Probst P, Levine JG. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: Results of three US multicenter, double blind trials. Am J Gastroenterol 2000;95:3393-3398.
    
  • Fennerty MB, Corless CL, Sheppard B, Faigel DO, Lieberman DA, Sampliner RE. Pathologic documentation of complete elimination of Barrett's metaplasia following endoscopic MPEC therapy. Gut 2001;49:142-144.
    Ofmann JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing strategies for gastroesophageal reflux disease. Aliment Pharmacol Ther 2001 (in press).
    
  • Fennerty MB. Strategies for diagnosis and short and long-term treatment of GERD: Respondent overview. Am J Gastroenterol 2001;96 (8 suppl):S27-S28.
    
  • Sampliner RE, Faigel D, Fennerty MB, et al. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: A multicenter study. Gastrointest Endosc. 2001;53:544-8.
    
  • Fennerty MB. Is nonulcer dyspepsia related to Helicobacter pylori infection? Semin Gastro Dis 2001;12:180-185.
    
  • Fennerty MB. NSAID-related Gastrointestinal Mucosal Injury: An evidence-based approach to this common preventable complication. Postgrad Med 2001;110:87-94.
    
  • Fennerty MB. Triadafilopoulos G. Barrett's-related esophageal adenocarcinoma: Is chemoprevention a potential option? Am J Gastroenterol 2001;96:2302-2305.
    
  • Fennerty MB, Magaret N, Dalros L, Faigel D, Lieberman D, Shaw M. Outcomes of Helicobacter pylori treatment in community practice and impact of therapeutic effectiveness information on physician behavior. Aliment Pharmacol Ther 2001;15:1453-8.
    
  • Faigel DO, Lieberman DA, Weinstein WM, Fanning S, Fennerty MB, Sampliner RE. Effect of multipolar coagulation on the endosonography of Barrett's esophagus. Gastrointest Endosc 2001. (In Press).
    
  • Lieberman DA, Weiss DG, Fennerty MB,et al. One time screening for colorectal cancer with combined fecal occult blood testing and examination of the distal colon. N Engl J Med 2001;345:555-560.
    
    
• Biosketch:
  
  

  M. Brian Fennerty, MD, is Professor of Medicine in the Division of Gastroenterology at Oregon Health & Science University (OHSU) in Portland, Oregon. He is also Section Chief of Gastroenterology at OHSU.
  
  Dr. Fennerty is an authority on gastroesophageal reflux disease, Barrett’s esophagus, and Helicobacter pylori. He has published more than 300 papers, book chapters, and abstracts. He is currently the Editor of Journal Watch Gastroenterology and Reviews in Gastroenterological Disorders and the past Associate Editor of American Journal of Gastroenterology and Clinical Perspectives in Gastroenterology. He also serves on the editorial board of a number of professional publications, including Archives of Internal Medicine, Gastrointestinal Endoscopy, Alimentary Pharmacology and Therapeutics, and Evidence-Based Gastroenterology.
  
  Dr. Fennerty is a past member and current consultant of the FDA Advisory Panel on Gastrointestinal and Urological Devices as well as the past chair of the Imaging and Advanced Technology section of the AGA and the Research Committee of the American Society for Gastrointestinal Endoscopy and is currently the Secretary and member of the Governing Board of the ASGE.